Three things send the market higher these days: i) optimism that Congress will finally renew the fiscal stimulus which expired on July 31; ii) optimism that a covid vaccine will miraculously fix the global economy, and iii) in a throwback to 2019 optimism on the US-China trade deal. We got a dose of iii) late on Monday when the USTR reported that top U.S. and Chinese trade officials reaffirmed their commitment to a Phase 1 trade deal which has seen China lagging on its obligations to buy American goods, with a call (originally scheduled for Aug 15) in which both sides saw "progress and are committed to taking the steps necessary to ensure the success of the agreement", and demonstrating a willingness to cooperate even as tensions rise over issues ranging from data security to democracy in Hong Kong.
Given the exchanges between the U.S. and China recently "have been negative, any small bit of positivity is seen as a big step forward, even when it isn’t," said David Madden, market analyst at CMC Markets UK. It was certainly enough to push US equity futures higher for a fourth straight session, with the Emini punching to a new all time of 3,448.75 during the Asian session which saw shares rise throughout most of Asia, before trimming gains to around 3,440 after the European open.
The S&P 500 and Nasdaq both clocked new record highs on Monday, with the benchmark index surpassing its pre-pandemic high last week even as recent economic data pointed to a wobbly recovery from the virus-led downturn. However, even as the ES was up some 0.3%, Nasdaq futures were shockingly in the red sparking panic and hysteria among a generation of retail daytraders who have never seen a red open in a centrally-planned market.
Salesforce.com, Amgen and Honeywell climbed between 3.6% and 4% premarket on news they would join the blue-chip Dow Jones Industrial Average index on Aug. 31. This came at the expense of three companies that are getting kicked out of the DJIA including E&P titan and formerly world's most valuable company Exxon Mobil, Pfizer and Raytheon Technologies which were down between 1.5% and 2.4%. Best Buy dropped despite reporting earnings that beat on the top and bottom line; Folgers coffee maker JM Smucker medical device maker Medtronic are also due to report quarterly results before the opening bell.
Investors also remain focused on vaccine progress as global economies reopen. Moderna said it’s near a deal to supply at least 80 million vaccine doses to the European Union.
"A steady flow of progress with Covid-19 treatments/vaccines is delivering the latest boost to risk appetite," said Oanda senior market analyst Edward Moya, but just like Morgan Stanley, he cautioned that "market breadth however does not support the surge to record high territory for U.S. indexes."
European stocks advanced for a second day after the latest IFO surveys showed German companies turning slightly more optimistic on the economic recovery despite missing expectations on, well, expectations:
- Ifo Expectations 97.5 vs. Exp. 98.0 (Prev. 96.7)
- Ifo Current Conditions 87.9 vs. Exp. 87.0 (Prev. 84.5)
- Ifo Business Climate 92.6 vs. Exp. 92.1 (Prev. 90.4)
The current assessment continues to lag expectations about the future, a reversal to pre-covid days.
The Stoxx Europe 600 Index climbed 0.4% as of 10:28 a.m. in London, with travel stocks advancing more than 2% and leading gains among sectors.
In Asia, markets were broadly higher, with Tokyo, Taipei, Seoul and Sydney all in the green while peers in Hong Kong and Shanghai slipped. South Korea's Kospi Index gained 1.6% and Jakarta Composite rising 1.2%, while Shanghai Composite dropped 0.4%. Japan's Topix gained 1.1%, with Globeride and Land Co rising the most. The Shanghai Composite Index retreated 0.4%, with Jiangxi Hongdu Aviation Industry and Dalian Bio-Chem posting the biggest slides.
In rates, treasuries traded heavy into early U.S. session with yields cheaper by 1bp-4bp across the curve in bear-steepening move. Treasury 10-year yields close to cheapest level of the day at 0.684%, highest in several days; long-end-led losses steepen 2s10s, 5s30s by ~2bp. Factors weighing on the curve include IG credit issuance, start of Treasury auction cycle and grind higher in S&P 500 futures. In Europe, Bunds lag Treasuries by 2bp while gilts trade broadly in line. As Bloomberg notes, concession starts to build into front-end also with $50b 2-year note sale at 1pm ET, ahead of $51b 5-year Wednesday and $47b 7-year Thursday.
In FX, the dollar and yen have softened against most currencies, while the euro has been topping the top-performing list as Action Economics recaps. This dynamic has come amid risk-on positioning in global markets. EUR-USD lifted to the mid 1.1800s, posting an intraday peak at 1.1843, which is 60 pips up on Monday's New York closing level. The euro has also rallied against the yen, which is the day's biggest loser, and most other currencies. While a bout of general dollar selling has helped to lift EUR-USD, there have concurrently been a couple of cues to buy euros, including August German Ifo business climate indicator, which beat forecasts in rising to a headline reading of 92.6, and remarks from German finance minister Scholz, who said there are signs that the German economy is developing above forecasts. USD-JPY, meanwhile, posted an eight-day high at 106.38, which is a gain of just over 40 pips on yesterday's closing level. The biggest mover out of the main currency pairings and crosses was EUR-JPY, which was showing over a 0.8% gain. The cross printed a six-day high at 125.97. GBP-JPY was not far behind, while AUD-JPY was showing a near 0.5% upward advance. Cable pegged an intraday high at 1.3126. USD-CAD posted a five-day peak at 1.3240 in pre-London trading, subsequently settling lower.
In commodities, oil was slightly higher as traders kept a watchful eye on Tropical Storm Laura, which is expected to strengthen into a hurricane before making landfall later this week. U.S. gasoline futures rose to the highest level since March on concern over possible fuel shortages. Elsewhere, gold dipped as low as $1,922 an ounce trading in a narrow range.
Looking at today's calendar, we’ll get the FHFA house price index for June, new home sales or July, as well as the Conference Board’s consumer confidence reading and the Richmond Fed manufacturing index for August. The Conference Board is expected to show U.S. consumer confidence improved slightly in August after falling more than expected in July amid a flare up in coronavirus cases. Otherwise, San Francisco Fed President Daly will be speaking, and earnings releases include Salesforce, Medtronic, Intuit and Autodesk. Investors also await Federal Reserve Chairman Jerome Powell’s address on Thursday for hints on the central bank’s next steps to support an economic recovery.
- S&P 500 futures up 0.3% to 3,439.25
- STOXX Europe 600 up 0.4% to 372.29
- MXAP up 0.3% to 172.99
- MXAPJ up 0.2% to 572.19
- Nikkei up 1.4% to 23,296.77
- Topix up 1.1% to 1,625.23
- Hang Seng Index down 0.3% to 25,486.22
- Shanghai Composite down 0.4% to 3,373.58
- Sensex up 0.06% to 38,824.20
- Australia S&P/ASX 200 up 0.5% to 6,161.39
- Kospi up 1.6% to 2,366.73
- German 10Y yield rose 2.1 bps to -0.47%
- Euro up 0.3% to $1.1817
- Italian 10Y yield unchanged at 0.819%
- Spanish 10Y yield rose 3.3 bps to 0.36%
- Brent futures up 0.3% to $45.28/bbl
- Gold spot down 0.1% to $1,926.57
- U.S. Dollar Index down 0.3% to 93.06
Top Overnight News from Bloomberg
- The U.S. and China reaffirmed their commitment to the phase-one trade deal in a biannual review, demonstrating a willingness to cooperate even as tensions rise over issues ranging from data security to democracy in Hong Kong
- Germany’s coronavirus daily new cases increased at a pace not seen for almost four months
- Moderna Inc. has announced it is close to a deal with the EU to provide at least 80 million vaccine doses
- Storm Laura is expected to be upgraded to a hurricane when it makes landfall on the American gulf coast in the next few days, leading U.S. gasoline futures to rise to their highest since the start of the pandemic on fears over potential fuel shortages
Courtesy of NewsSquawk, here is a quick recap of global markets:
Asian equity markets were mixed after trading mostly higher as the region initially took impetus from the fresh record highs on Wall St where cyclicals outperformed and with risk appetite also spurred by COVID-19 plasma treatment hopes, as well as reports US and China’s top trade negotiators held a constructive conversation on the Phase 1 agreement. ASX 200 (+0.5%) was led by tech and financials although gains in the benchmark index were capped by resistance at the 6200 level and amid headwinds from a deluge of earnings, while Nikkei 225 (+1.4%) outperformed as exporters cheered recent currency weakness and with the government to ease the ban on foreign residents returning to the country. Hang Seng (-0.3%) and Shanghai Comp. (-0.4%) also began higher after the PBoC boosted its liquidity efforts with a total CNY 300bln of reverse repo operations and following talks between USTR Lighthizer, Treasury Secretary Mnuchin and China’s Vice Premier Liu He in which both sides saw progress and were committed to taking the next steps required to ensure the success of the deal. However, gains later faded given that discussions were not much of a surprise and with the PBoC distancing itself from lowering capital requirements for bank, while Hong Kong was also cautious ahead of Chief Executive Lam’s announcement on social distancing arrangements later today as the current restrictions which limits public gatherings to two people are set to expire. Finally, 10yr JGBs were lacklustre with price action contained below the 152.00 level after weakness in T-notes and demand sapped by the gains in stocks, with the 20yr JGB auction doing little to spur prices despite printing improved results.
Top Asian News
- U.S., China Signal Progress on Trade Deal as Relations Fray
- Hong Kong to Relax Social Distancing Rules as Virus Cases Drop
- Credit Suisse’s Head of Asia Technology to Join Xiaomi as CFO
- Thai Cabinet Approves Extension of Emergency for Another Month
Stocks in Europe trade with modest gains (Euro Stoxx 50 +0.6%) albeit off highs, as sentiment somewhat improved following the mixed APAC lead. Some suggest that the “constructive” US-Sino trade call is spurring risk assets. However, it is worth remembering that there has been no new progress/developments in terms of trade, and in the grand scheme of things, US-Sino relations remain at all-time-lows on a number of fronts – e.g. geopolitics, capital markets and technology. On the data front – the German Ifo survey showed optimism in the country has increased, but economists noted that the German recovery is fragile and stocks were largely unfazed by the release. Sectors are mostly in the green, although the cyclical tilt seen at the open has somewhat faded, but nonetheless, financials and travel & leisure hold their top positions in the region, whilst materials and energy lag amid the price action in their respective complexes. In terms of individual movers, Aveva (+3.9%) holds onto gains after announcing a proposed acquisition of Osisoft for an enterprise value of USD 5bln. Nokia (+0.5%) and Ericsson (+1.2%) remain firm after reports noted that the Indian government is looking to phase out equipment from Chinese companies including Huawei from its telecoms network amid border tensions – with Nokia and Ericsson potentially to gain from this. On the flip side, Swisscom (-1.0%) is subdued after Swiss competition watchdog opened a probe into the Co. amid suspected abuse of market position within the broadband sector.
Top European News
- German Businesses Signal Optimism Recovery Is on Track; Germany Closes In on Agreement to Extend Job-Preserving Aid
- Credit Suisse to Cut Branches, Staff by Merging Swiss Unit
- Vanishing Jobs and Empty Offices Plague Britain’s Retailers
- Italy Clashes With Ex- Monopoly Over Future of Phone Network
In FX, as the DXY hovers just above the 93.000 level within a confined 93.012-351 band, major Dollar counterparts are also sitting close to big figures awaiting firm breaks or clearer direction, like the Euro in wake of an encouraging German Ifo survey on balance. To recap, 2 out of the 3 metrics exceeded expectations, but the more forward looking outlook reading missed consensus remains the institute was reserved in describing the economic recovery as fragile. Hence, Eur/Usd was toppy ahead of yesterday’s peak and hefty option expiry interest close by at 1.1850 in 1 bn. Meanwhile, Cable continues to pivot 1.3100 ahead of CBI trades and amidst the ongoing threat of Britain leaving transition without a Brexit trade deal, and the Franc is still tethered to 0.9100 after a dip in Swiss Q2 payrolls was largely nullified by an upward revision to the previous quarter. However, the Yen has retreated through 106.00 and into a lower range on a loss of safe-haven premium and with US Treasury yields backing up before this week’s auctions amidst curve re-steepening.
- NZD/AUD/CAD - The Kiwi is holding above 0.6500 in advance of NZ trade data and the Aussie has gleaned more indirect support from another firm PBoC CNY fix that in turn has given the CNH fresh impetus to test 6.9000 vs the Greenback. Aud/Usd is meandering between 0.7152-82 following mixed independent impulses overnight via an improvement in ANZ weekly consumer confidence in contrast to labour data revealing a 1% decline in jobs for the month to August 8 and 2.8% drop in the state of Victoria for a national fall of 4.9% relative to mid-March (pre-pandemic or the ‘first’ wave as such). Conversely, the Loonie is licking wounds beneath 1.3200 and detached from choppy oil prices following Canada’s appeal to the WTO against US soft lumber levies.
- SCANDI/EM - Marginal Nok outperformance even though Norwegian GDP was a bit weaker than forecast in Q2, but the Try has not derived much traction on the back of a rise in Turkish manufacturing sentiment and the Rub is not tracking the firm tone in Brent against the backdrop of ongoing geopolitical/diplomatic tensions that are also weighing on the Lira.
In commodities, WTI and Brent front month futures remain relatively flat in early European trade, with the benchmark only some USD 0.2-0.3/bbl off overnight lows. Traders are keeping a keen eye on the developments in the Gulf of Mexico as Tropical Storm Laura is forecast to evolve into a major hurricane before making landfall late-Wednesday, whilst Marco was downgraded to a Tropical Depression. On that front, the latest update from the Search Results Bureau of Safety and Environmental Enforcement (BSEE) estimates around 82.4% of current oil production shuttered – with the next release scheduled for 1400ET/1900BST. WTI Oct resides around USD 42.50/bbl (vs. low ~42.30/bbl), whilst its Brent counterpart trades around USD 45.25/bbl (vs. low USD 45.08/bbl). Traders will now be eyeing the weekly release of the Private Inventories in the absence of macro headlines – albeit price action could be muted as hurricane developments are timelier. Elsewhere, spot gold trades choppy within a tight range on either side of USD 1930/oz whilst spot silver sees similar action around 26.50/oz – both moving in tandem with the Buck ahead of Fed Chair Powell’s speech on Thursday. In terms of base metals, Dalian iron ore prices fell some 3.5% whilst Shanghai steel rebar edged lower as downstream demand recovery missed market forecasts. Conversely, Shanghai nickel prices rose almost 2% at one point amid dwindling Chinese port inventories.
US Event Calendar
- 9am: FHFA House Price Index MoM, est. 0.3%, prior -0.3%; House Price Purchase Index QoQ, prior 1.7%
- 9am: S&P CoreLogic CS 20-City MoM SA, est. 0.1%, prior 0.04%; YoY NSA, est. 3.6%, prior 3.69%
- 10am: Conf. Board Consumer Confidence, est. 93, prior 92.6; Present Situation, prior 94.2; Expectations, prior 91.5
- 10am: New Home Sales, est. 790,000, prior 776,000; MoM, est. 1.8%, prior 13.8%
- 10am: Richmond Fed Manufact. Index, est. 10, prior 10
DB's Jim Reid, freshly back from vacation, concludes the overnight wrap
If you’d have told me at the start of the year that at the end of August I’d be quarantining with my family and not allowed to leave the perimeter of my garden then I’d have been extremely worried and assumed that one of my children had dug up the bubonic plague. Thankfully it’s less worrisome than that and instead because I was on holiday in the French Alps and new travel rules now apply back to the U.K from France. Ironically the French Alps have hardly seen new cases rise even if they have in say Paris and parts of the South of France. So if you’d have got back two days before me from Paris you wouldn’t have to quarantine but I do from the Alps. We still had to cut our holiday short by a week to ensure the children didn’t miss their first days at school next week. Elite athletes are exempt from these rules but after trying to show the customs officer at the Channel Tunnel my golf swing I wasn’t given special dispensation.
So we’ve been looking after three young terrors at home over the last week and it’s been painful with nothing to do or nowhere to go. Bronte also doesn’t understand why she doesn’t get walked. All first world problems admittedly but I really don’t understand those that say the best thing about Covid is that you get to spend more time with your family. I love them all dearly but an hour or two a day is ideal (that doesn’t include my wife by the way).
So I actually mean it when I say it’s good to be back in my home office mentally and physically quarantining from the kids. Over the holiday I’ve been thinking a lot about the virus and the way forward and I continue to scratch my head about the end game. Within the next few weeks we should know much more about the state of play with regards to the leaders in the vaccine race (supportive news yesterday for the AstraZeneca/Oxford Uni version as we’ll see below). That’s probably going to be the most important newsflow of the next month or so. We’re trying to collate as much info as possible on the current state of play with vaccines and will try to put out a piece next week on where we are at. Obviously if a vaccine gets approved in the coming weeks then we’ll likely have a realistic end game within months as I’m sure we’ll go into mass production very quickly.
However without a vaccine it feels like global strategies are very difficult to decipher. When lockdowns started back in March the main rational was to ensure health services did not get overrun. Five months on, the number of Covid cases in hospitals are relatively low in many areas and yet many countries seem to be trying to keep cases as low as possible as a badge of honour and the world has got so scared that such a strategy seems to meet high approval. Countries that are seeing cases rise are looked at with great suspicion even if hospitalisations are still relatively low. However is such suppression a sustainable strategy? Given this is happening in the northern hemisphere summer I can’t help wondering where we’ll be in two or three months time and what the reaction will be from the authorities.
The good news is that there continues to be plenty of evidence that those catching the virus seem to be from younger, less vulnerable cohorts and this seems to be contributing to a lower and lower case fatality rate across the globe alongside better treatment and possibly the virus mutating. To be fair listening to politicians the bar to renewed full lockdowns seems to be high around the world, but equally the bar to getting to anything resembling normality also seems very high. So we are in Covid limbo until a vaccine or a yet unidentified master plan materialises. All ahead of a northern hemisphere autumn and winter when life will naturally move more indoors.
To be fair all of this continues to be a passing curiosity to the US equity market which continues to hit new highs even if the breadth of the winners has narrowed further in recent weeks. Yesterday showed some signs of rotation and catch up from the laggards though, which helped push the S&P 500 up a further +1.00%, having already risen for 7 of the last 8 weeks. The move took the index to another record high and puts it +6.03% on a YTD basis. The airline industry led the S&P yesterday, gaining +8.23% as optimism on a possible vaccine buoyed the beaten down industry higher. In fact American Airlines (+10.53%), Carnival (+10.17%), United (+9.93%), Delta (+9.28%) and Norwegian Cruise Line (+7.58%) were five of the seven best performing stocks in the index. Elsewhere, tech stocks underperformed as there was some rotation out of biotechs (-0.47%) in particular. The Nasdaq closed +0.60% higher yesterday (also to a new record) with the tech-dominated index now standing at an astonishing +26.83% higher YTD.
On the vaccine news, AstraZeneca shares were up +2.06% following the FT report that the Trump administration could bypass normal regulatory standards for the Oxford vaccine. As the election approaches it seems inevitable that Mr Trump will want to encourage as much positivity on the virus as is in his power. So one to watch.
Oil prices were buoyant as well yesterday, with Brent crude up +1.76% to $45.13/bbl in a move that wiped out all of last week’s declines and helped energy stocks lead the equity advance on both sides of the Atlantic. Over in Europe, equities saw even bigger moves higher, with the STOXX 600 up +1.58% and the DAX up +2.36%.
The rotation into risk assets saw sovereign bonds lose ground somewhat yesterday, and yields on 10yr Treasuries were up +2.6bps by the close. With market participants awaiting Fed Chair Powell’s speech at Jackson Hole for any policy hints, our global head of rates research Francis Yared wrote a blog post yesterday (link here) in which he says that a lot of the expected dovishness is already priced into markets. As a result, only a material upsizing in QE should have a material market impact. There was a similar pattern for European rates too yesterday, where yields on 10yr bunds (+1.6bps), OATs (+0.9bps) and gilts (+0.7bps) all rose. And in line with this retreat from safe assets, gold extended its falls from the previous week with a further -0.60% decline. It’s now -6.53% off its highs 3 weeks ago.
Overnight the key news has been that the US and China’s top trade negotiators discussed the Phase 1 trade deal last night and the US concluded that both sides saw progress and are committed to its success. The US statement said that “The parties also discussed the significant increases in purchases of US products by China as well as future actions needed to implement the agreement,” while adding that China has made progress on other commitments like taking steps to ensure greater protection for intellectual property rights and removing impediments to American companies in the areas of financial services.
Asian markets are mostly positive this morning outside of China and HK which are seeing the Hang Seng (-0.53%) and Shanghai Comp (-0.19%) both down. The Nikkei (+1.84%), Kospi (+1.44%) and Asx (+0.42%) are up though alongside futures on the S&P 500 (+0.46%). Elsewhere, gold and silver prices are also up +0.39% and +0.49% and in agriculture commodities, CBT soybeans and corn future prices are up +1.10% and +1.52% respectively.
On the coronavirus and as alluded to at the top, countries around the world continue to re-implement restrictions at the first uptick in cases. Zurich has announced new limits on social gatherings of up to 100 unless masks are worn and have mandated that masks must be worn within shops. This followed news that the Netherlands have issued 10-day quarantine measures on all travelers from Spain, as well as the majority of travelers from France. This comes as Spain posted four month highs in cases last week. In what may be a harbinger for the colder month’s ahead, Germany is planning to stop testing people returning from hotspots, citing a lack of testing capacity for the virus. Those travelers will still have to undergo quarantine measures and will have to get tested themselves in order to exit their quarantine early. These measures weighed on the STOXX 600 Travel and Leisure stocks (-0.09%), which did not see the same performance as their American counterparts on the upbeat vaccine news.
We did get further signs of stabilisation in new cases in the United States though, with Florida reporting the lowest number of new cases since mid-June yesterday, while New York state saw their infection rate fall to 0.66%, the lowest since the beginning of the pandemic. In a sign of further normalization following the recent uptick in cases, Apple announced plans to reopen some of the over 120 stores that they had reclosed during the summer outbreak. This could happen as soon as the end of this month. Across the other side of world, Singapore has identified a total of 58 cases in the country’s largest foreign workers dormitory which houses c. 16,000 people and as a precaution has placed another 4,800 workers from the same dormitory on stay-home notices. Meanwhile, South Korea added a further 280 cases in the past 24 hours up from 266 a day earlier and also ordered kindergarten, elementary, middle and high schools in the greater Seoul area to shift to online classes from partial attendance. Elsewhere, Qantas Airways said overnight that it will cut an additional 2,500 jobs due to the COVID impact on top of the earlier announced plans to eliminate 6,000 jobs or 20% of the workforce.
To the day ahead now, and data highlights from Germany include the Ifo business climate indicator for August along with the final reading of Q2’s GDP. Meanwhile in the US, we’ll get the FHFA house price index for June, new home sales or July, as well as the Conference Board’s consumer confidence reading and the Richmond Fed manufacturing index for August. Otherwise, San Francisco Fed President Daly will be speaking, and earnings releases include Salesforce, Medtronic, Intuit and Autodesk.
Plan will put everyone in England within 15 minutes of green space – but what matters is justice not distance
The UK government wants every household in England to be within 15 minutes walk of a park, woodland or water.
How long does it take you to walk to your nearest park, woodland, lake or river? If it takes more than 15 minutes, according to the UK government’s new environmental improvement plan for England, something needs to be done about it. It says 38% people in England don’t have a green or blue space within a 15-minute walk of their home.
The plan promises a “new and ambitious commitment to work across government and beyond” to provide access to local green and blue spaces. It recognises the importance of connecting with nature, and that time spent outdoors is good for physical and mental health.
That’s a message researchers have been underlining for years, as a recent evidence review shows, and it has been amplified by COVID-19, which showed the importance of local green and blue spaces for wellbeing.
But the plan’s laudable ambitions overlook the ways our experiences of the outdoors are shaped by privileges of wealth and health.
If you live in a disadvantaged area, your local green space may be further away from your home, or you might have to share it with more people. As the campaign group Fields in Trust pointed out in a 2022 report, this is a question of justice.
However, there’s more to justice than the amount of space you have to share with others, or how long it takes you to get there. It’s also about how you feel and what you can do when you get there.
My own research highlights some key questions we need to ask if we’re to protect and improve our green spaces for future generations. Questions such as “Do I feel welcome here?” “Does this space meet my needs?” or “Do I get a say in how it is looked after?” highlight the fact that access is a matter of equality and democracy.
Some green spaces are greener than others
There are three key aspects of green and blue spaces that should be considered, and invested in, if the environmental improvement plan is to be more than wishful thinking.
First, not all green and blue spaces are the same or provide the same benefits. The qualities of a football pitch are very different from those provided by a woodland walk along a stream.
Lumping them all together as “green and blue spaces” overlooks the need for a variety of spaces within easy reach to meet local people’s needs for physical and mental wellbeing.
Second, not all spaces are equally well looked after. Spaces that are fly-tipped or associated with antisocial activities can feel intimidating, especially after dark.
Green and blue spaces in disadvantaged areas need more care, and that requires time and money. As Public Health England noted, access to good quality green spaces is worse in more disadvantaged areas.
Third, simply being in a space won’t necessarily bring you all the benefits a space can offer. For people suffering from anxiety or depression, for example, more structured activities might be more helpful.
Be like Birmingham
In Birmingham, the local authority isn’t content with trumpeting the merits of its 600 parks. Instead, the city has developed a city of nature plan (I was part of a team that evaluated it).
At the heart of its approach is the idea of environmental justice, which it defines as “the fair treatment and meaningful involvement of all people regardless of race, colour, national origin, or income, with respect to the development, implementation and enforcement of environmental laws, regulations, and policies”.
To apply environmental justice to the city’s green spaces, Birmingham Council has assessed each of its 69 electoral ward in terms of access to green space of two hectares (about three football pitches) or more within 1,000 metres, as well as flood risk, urban heat island effects, health inequalities and deprivation.
Through this work, it has identified 13 of its 69 wards which are most in need of investment to reach a new “fair parks standard”. These mainly central areas have less accessible green space, are more at risk of flooding and urban heating, and are more deprived.
Starting with a pilot programme in Bordesley & Highgate Ward (setting for the BBC series Peaky Blinders), the plan is then to invest in a further five priority areas in central and east Birmingham: Balsall Heath West, Nechells, Gravelly Hill, Pype Hayes and Castle Vale.
This is the kind of approach that could guide investment in many other cities. It links funding with equalities and brings together climate change, public health and community issues. It shows that quality and equity can’t just be boiled down to the distance between your home and the nearest park.
The challenge now is to learn from Birmingham’s pioneering approach and apply similar principles elsewhere. At its best, this work can be used to highlight the challenges not only of applying resources equitably, but of ensuring the resources are there in the first place, an issue the environmental impact plan rather predictably glosses over.
Julian Dobson and colleagues were funded by the National Trust and National Lottery Heritage Fund to evaluate the Future Parks Accelerator programme. The views expressed here are the author's own.depression covid-19 treatment uk
UN Initiative Targets And Doxxes Doctors And Nurses Who Don’t Follow COVID-19 Narrative
UN Initiative Targets And Doxxes Doctors And Nurses Who Don’t Follow COVID-19 Narrative
Authored by Katie Spence via The Epoch Times (emphasis…
Authored by Katie Spence via The Epoch Times (emphasis ours),
Nicole Sirotek is a registered nurse in Nevada with over a decade of experience working in some of the harshest conditions. When a hurricane devastated Puerto Rico, Sirotek and the organization she founded, American Frontline Nurses (AFLN), were there and gave out over 500 pounds of medical equipment and supplies.
She hasn’t hesitated to be the first in when an emergency hits and medical professionals are needed. She’s lost count of the number of times she’s woken up on a cot in the middle of nowhere, boots still strapped to her feet, and ready to go.
But in tears during an interview with The Epoch Times, she detailed her ordeal with harassment and doxing over the past year and how she’s contemplated suicide due to crippling anxiety and depression.
“It took such a toll on my mental health. I wasn’t sleeping and wasn’t eating,” Sirotek said.
To regain her mental health, she decided to step back from the group she started. But even that decision brought pain.
“I said after I left New York, I’d do everything that I can to make sure it didn’t happen again,” Sirotek said, recalling the death she witnessed when she volunteered in New York as a nurse at the start of the COVID-19 pandemic. “I mean, for me to step back and take a break just makes me feel like I failed!”
Sirotek is the victim of ongoing harassment. She’s received pictures of her children posed in slaughterhouses and hanging from a noose, drive-by photos of her house, and letters with white powder that exploded upon opening.
The Nevada State Board of Nursing was inundated with calls for Sirotek’s professional demise and flooded with anonymous complaints.
In response, Sirotek filed a police report. Her lawyer sent a cease-and-desist letter. The Epoch Times reviewed the documents.
The reply from the cease-and-desist letter? The client was acting within his First Amendment rights.
The Harassment Begins
In February 2022, Sirotek, as the face of AFLN, a patient advocacy network that boasts 22,000 nurses, appeared before Sen. Ron Johnson (R-Wis.) and testified about the harm patients were experiencing when they sought treatment for COVID-19.
She said she didn’t witness patients dying from the novel virus when she volunteered to work the front lines in New York at the start of the pandemic.
Instead, in her opinion, as a medical professional with multiple master’s degrees, patients were dying from “negligence” and “medical malfeasance.”
Sirotek detailed the withholding by higher-ups of steroids and Ibuprofen and the prescribing of remdesivir. Additionally, there was zero willingness to consider possible early intervention treatments like ivermectin.
As the pandemic continued, such practices only escalated, Sirotek said.
Sirotek’s testimony resulted in cheers, widespread attention, and a target on her back.
“[The harassment] all started the day we got back from DC,” Sirotek said.
At first, the attacks started with the typical “you’re transphobic, you’re anti-LGBTQ. I mean, they even called me racist,” Sirotek, who is Hispanic, recalled.
And as more patients sought AFLN’s help, the attacks increased in frequency and force.
At first, Sirotek said the attacks appeared to come from random people. But as the attacks continued, the terms “Project Halo,” “Team Halo,” and “#TeamHalo” continually cropped up. Especially on TikTok and from two accounts, “@jesss2019” and “@thatsassynp.”
“[@thatsassynp] just kept on saying how I was spreading misinformation, [that] ivermectin doesn’t work,” Sirotek said. “He kept targeting the Nevada State Board of Nursing because I was on the Practice Act Committee, and he did not feel like that was acceptable.”
Craig Perry, a lawyer representing nurses, including Sirotek, before the Nevada State Board of Nursing, confirmed Sirotek’s account. The executive director of the Nevada State Board of Nursing, Cathy Dinauer, declined to provide details on complaints or investigations, stating to The Epoch Times via email that they are “confidential.”
Sirotek said the complaints overwhelmed her ability to defend her nursing license.
“Untimely, they were filing so many complaints against me that [the Nevada State Board of Nursing] had to start filtering them as to what was applicable and not applicable. And [the complaints] just buried my nursing license to the point that we couldn’t even defend it,” Sirotek said.
Attacks Transition to Threats
Whenever Sirotek, or AFLN, tried to set up a community outreach webinar, hateful comments flooded their videos.
Julia McCabe, a registered nurse and the director of advocacy services for AFLN, told The Epoch Times that initially, they tried kicking the trolls out of the outreach videos. But they couldn’t keep up with the overwhelming numbers and had to shut the videos down, usually after only 10 minutes, she said.
To address the swarms, as McCabe labeled them, AFLN started charging an entrance fee for their webinars. But, McCabe said, they’d send out an email with a free access code to all of their subscribers before the webinar started. It helped, but not enough. The swarms kept coming. And the attacks escalated.
On June 5, 2022, @thatsassynp posted a video on TikTok calling for a “serious public uprising,” because the Nevada State Board of Nursing and other regulatory agencies weren’t disciplining nurses for spreading “disinformation.”
It became one of many such videos in the ensuing days. In the comments of one, he stated, “Also, stay tuned as [@jesss2019] will be addressing this as well. We are teaming up (as per usual) to raise awareness and demand action on this issue.” @jesss2019 responded, “Yes!!!! We will get this taken care of.”
Jess and Tyler Kuhk of @thatsassynp have “teamed up” on several occasions, targeting healthcare workers who question the COVID-19 narrative. Team Halo doesn’t officially list Kuhk on its site, but Kuhk posts with the #teamhalo.
In another video, he states, “If you’re new to this series, PLEASE watch the videos in my playlist ‘Nevada board of nursing.’ This started in Feb of this year.” His video has almost 35,000 “loves.”
On June 7, 2022, @jesss2019 posted a video on TikTok accusing Sirotek of spreading misinformation. It included a link to @thatsassynp, and his complaints about Sirotek to the Nevada State Board of Nursing and calls to remove her from the Practice Act Committee. She implored TikTok to boost the message. It, too, became one of many videos attacking Sirotek.
Specifically, @jesss2019 and @thatsassynp took issue with videos and posts from Sirotek, and AFLN, advocating for ivermectin and highlighting possible issues with remdesivir and the COVID-19 vaccines.
@jess2019 removed all of the above videos after The Epoch Times sought comment. The Epoch Times retains copies.
Sirotek says she received the first death threat against herself and her children around the same time, in June 2022.
“They cut off the pictures of my children’s faces from our family photos, where we take them every year on our front porch—we’ve got 11 years of those photos—and they cut them out and put them on the bodies of those little boys that have been sexually abused. And that’s what would get sent to my house. And I gave the police that,” Sirotek said.
In response to a request for comment from The Epoch Times, Sen. Johnson defended Sirotek.
“The COVID Cartel continues to frighten and silence those who tell the truth and challenge their failed response to COVID,” Johnson said. “It is simply wrong for Ms. Sirotek to be smeared and attacked like so many others who have had the courage and compassion to successfully treat COVID patients.”
As the threats continued and escalated, Sirotek also asked Perry to send a cease-and-desist letter to Tyler Kuhk on Aug. 1, 2022.
Kuhk, a nurse practitioner, is the person posting on TikTok under the pseudonym @thatsassynp.
The letter sent to Kuhk alleges that on at least 10 different occasions, @thatsassynp encouraged a “public uprising” against Sirotek. It also details that his videos attacking Sirotek garnered over 400,000 views.
In response, McLetchie Law, a “boutique law firm serving prominent and emerging … media entities” responded to Perry by stating in a letter dated Aug. 16, 2022, “Both Nevada law and the First Amendment provide robust protections for our client’s (and others’) rights to criticize Ms. Sirotek’s dangerous views and practices—and to advocate for her removal from the Nursing Practice Advisory Committee of the Nevada State Board of Nursing.”
It also warned that any attempt to deter Kuhk from his chosen path would “backfire” and could result in a “negative financial impact.” Neither Kuhk nor McLetchie Law responded to The Epoch Times’ request for comment.
Unable to confirm the real name behind the TikTok account @jesss2019, and thus, unable to send her a legal letter, Sirotek posted some of the threats she’d received on Facebook, pleading for @jesss2019 to cease targeting her, and recognize the possible real-world harm.
In desperation, Sirotek asked Perry to file a legal name change, which he did on Sep. 15, 2022, hoping that would thwart people’s ability to look up Sirotek’s information. Perry told The Epoch Times, “Usually, when you do a name change, it’s a public record. But under extenuating circumstances, you can have that sealed.”
In Sirotek’s case, the court recognized the threat to her and her family’s safety, waived the publication requirement, granted the change, and sealed her record on Oct. 4, 2022.
Sirotek, at the behest of Perry, filed a police report detailing the harassment on Oct. 17, 2022.
In December 2022, @jesss2019 posted a video to TikTok doxing Sirotek by revealing her name change. The Epoch Times sought comment from @jesss2019 but has not received a response. After the request for comment, the user removed the video.
Team Halo and Social Media
On Dec. 17, 2020, Theo Bertram, a director at TikTok; Iain Bundred, the head of public policy at YouTube; and Rebecca Stimson, the UK head of public policy for Facebook, appeared before the UK’s House of Commons to explain what their social media sites were doing to combat “anti-vaccination disinformation.”
All three stated their companies employed a “two-pronged approach.” Specifically, “tackle disinformation and promote trusted content.”
Bundred stated that from the beginning of the year to November 2020, YouTube had removed 750,000 videos that promoted “Covid disinformation.”
Stimson stated that between March and October 2020, “12 million pieces of content were removed from [Facebook],” and it had labeled 167 million pieces with a warning.
Bertram stated that for the first six months of 2020, TikTok removed 1,500 accounts for “Covid violation” and had recently increased that activity. “In the last two months, we took action against 1,380 accounts, so you can see the level of action is increasing,” Bertram said.
“In October, we began work with Team Halo,” Bertram added. “I do not know if you are familiar with Team Halo. It is run by the Vaccine Confidence Project at the London School of Hygiene and Tropical Medicine and is about getting reliable, trusted scientists and doctors on to social media to spread trusted information.”
Team Halo’s Origins
On Sep. 20, 2022, Melissa Fleming, the under-secretary-general for global communications at the United Nations, appeared at the World Economic Forum to discuss how the United Nations was “Tackling Disinformation” regarding “health guidance” as well as the “safety and efficacy of the vaccine” for COVID-19.
“A key strategy that we had was to deploy influencers,” Fleming stated. “Influencers who were really keen, who had huge followings, but really keen to help carry messages that were going to serve their communities.”
Fleming also explained that the United Nations knew its messaging wouldn’t resonate as well as influencers, so they developed Team Halo.
“We had another trusted messenger project, which was called Team Halo, where we trained scientists around the world, and some doctors, on TikTok. We had TikTok working with us,” Fleming said. “It was a layered deployment of ideas and tactics.”
Read more here...
Why Is There A COVID Vaccine Mandate For Students?
Why Is There A COVID Vaccine Mandate For Students?
Authored by Margaret Anna Alice via ‘Through The Looking Glass’ Substack,
Letter to the…
Letter to the Stanford Daily: Why Is There a COVID Vaccine Mandate for Students?
“Not to know is bad. Not to wish to know is worse.”
I can’t figure out why Stanford is mandating the COVID vaccine for students.
Is it to protect students from the virus, hospitalization, or death?
Is it to protect them from other students?
Is it to protect the Stanford community members from the students?
If it’s to protect the students from catching COVID, that doesn’t make sense because the CDC says it “no longer differentiate[s] based on a person’s vaccination status because breakthrough infections occur.”
The CDC also acknowledges natural immunity, noting that “persons who have had COVID-19 but are not vaccinated have some degree of protection against severe illness from their previous infection.”
It appears Stanford didn’t get the memo because Maxwell Meyer—a double-jabbed, COVID-recovered alum who was nearly prohibited from graduating for choosing not to get boosted—was informed by an administrator that the booster mandate is “not predicated on history of infection or physical location.”
Despite living 2,000 miles away from campus and not being enrolled in coursework for his final term, Maxwell was told Stanford was “uniformly enforc[ing]” the mandate “regardless of student location.” Does that sound like a rational policy?
Fortunately, a different administrator intervened and granted Maxwell an exemption, but few Stanford students are so lucky. Almost everyone else simply follows the rules without realizing they’ve volunteered for vaccine roulette.
A Cleveland Clinic study of the bivalent vaccines involving 51,011 participants found the risk of getting COVID-19 increased “with the number of vaccine doses previously received”—much to the authors’ surprise.
They were stumped as to why “those who chose not to follow the CDC’s recommendations on remaining updated with COVID-19 vaccination” had a lower risk of catching COVID than “those who received a larger number of prior vaccine doses.”
So if the vaccines don’t keep you from getting COVID, maybe they at least protect you from hospitalization?
That doesn’t wash, either, because according to data from the Coronavirus Disease 2019 (COVID-19)-Associated Hospitalization Surveillance Network (COVID-NET), hospitalization rates for 18–64-year-olds have increased 11 percent since the vaccine rollout. Worse, kids under 18 have suffered a shocking 74 percent spike in hospitalizations.
An observational study conducted at Germany’s University Hospital Wuerzburg found:
“The rate of adverse reactions for the second booster dose was significantly higher among participants receiving the bivalent 84.6% (95% CI 70.3%–92.8%; 33/39) compared to the monovalent 51.4% (95% CI 35.9–66.6%; 19/37) vaccine (p=0.0028). Also, there was a trend towards an increased rate of inability to work and intake of PRN medication following bivalent vaccination.”
A new paper published in Science titled Class Switch Towards Non-Inflammatory, Spike-Specific IgG4 Antibodies after Repeated SARS-CoV-2 mRNA Vaccination even has Eric Topol concerned:
Late after mRNA Covid vaccines, or with booster or breakthrough infections, there is a shift to IgG4 antibodies, not seen with adenovirus vector vaccines. The clinical significance is not knownhttps://t.co/5thLxRwemm @SciImmunology @UniFAU pic.twitter.com/YozSLVjVLd— Eric Topol (@EricTopol) December 22, 2022
If you don’t know what that means, Dr. Syed Haider spells it out in this tweet. He explains that the shots “train your immune system to ignore the allergen by repeated exposure,” the end result being that “Your immune system is shifted to see the virus as a harmless allergen” and the “virus runs amok.”
Latest IgG4 COVID vax study— Dr. Syed Haider (@DrSyedHaider) December 28, 2022
Think allergy shots. They train your immune system to ignore the allergen by repeated exposure.
That’s what repeated shots with the vax are doing.
Your immune system is shifted to see the virus as a harmless allergen.
Which means: virus runs amok.
Well, then does the vaccine at least prevent people from dying of COVID?
Nope. According to the Washington Post, “Vaccinated people now make up a majority of COVID deaths.”
At Senator Ron Johnson’s December 7, 2022, roundtable discussion on COVID-19 Vaccines, former number-one–ranked Wall Street insurance analyst Josh Stirling reported that, according to UK government data:
“The people in the UK who took the vaccine have a 26% higher mortality rate. The people who are under the age of 50 who took the vaccine now have a 49% higher mortality rate.”
Obtained by a Freedom of Information Act (FOIA) request to KBV (the association representing physicians who receive insurance in Germany), “the most important dataset of the pandemic” shows fatalities starting to spike in 2021.
Data analyst Tom Lausen assessed the ICD-10 disease codes in this dataset, and the findings are startling. His presentation includes the following chart documenting fatalities per quarter from 2016 to 2022:
This parallels the skyrocketing fatality rates seen in VAERS:
The vaccinated are more likely to contract, become hospitalized from, and die of COVID. If the vaccine fails on all of those counts, does it at least prevent its transmission to other students and community members?
The obvious answer is no since we already know it doesn’t prevent you from getting COVID, but this CDC study drives the point home, showing that during a COVID outbreak in Barnstable County, Massachusetts, “three quarters (346; 74%) of cases occurred in fully vaccinated persons.”
Maybe Stanford can tell us why they feel the mandate is necessary. Their booster requirement reads:
“Why does Stanford have a student booster shot requirement? Our booster requirement is intended to support sustained immunity against COVID-19 and is consistent with the advice of county and federal public health leaders. Booster shots enhance immunity, providing additional protection to individuals and reducing the possibility of being hospitalized for COVID. In addition, booster shots prevent infection in many individuals, thereby slowing the spread of the virus. A heavily boosted campus community reduces the possibility of widespread disruptions that could impact the student experience, especially in terms of in-person classes and activities and congregate housing.”
The claim that “booster shots enhance immunity” links to a January 2022 New York Times article. It seems Stanford has failed to keep up with the science because the very source they cite as authoritative is now reporting, “The newer variants, called BQ.1 and BQ.1.1, are spreading quickly, and boosters seem to do little to prevent infections with these viruses.”
Speaking of not keeping up, that same article says the new bivalent boosters target “the original version of the coronavirus and the Omicron variants circulating earlier this year, BA.4 and BA.5.”
It then goes on to quote Head of Beth Israel Deaconess’s Center for Virology & Vaccine Research Dan Barouch, who says, “It’s not likely that any of the vaccines or boosters, no matter how many you get, will provide substantial and sustained protection against acquisition of infection.”
In other words, Stanford’s rationale for requiring the boosters is obsolete according to the authority they cite in their justification.
If Stanford is genuinely concerned about “reduc[ing] the possibility of widespread disruptions that could impact the student experience,” then it should not only stop mandating the vaccine but advise against it.
Some nations have suspended or recommended against COVID shots for younger populations due to the considerable risks of adverse events such as pulmonary embolism and myocarditis—from Denmark (under 50) to Norway (under 45) to Australia (under 50) to the United Kingdom (seasonal boosters for under 50).
The Danish Health Authority explains why people under 50 are “not to be re-vaccinated”:
“People aged under 50 are generally not at particularly higher risk of becoming severely ill from covid-19. In addition, younger people aged under 50 are well protected against becoming severely ill from covid-19, as a very large number of them have already been vaccinated and have previously been infected with covid-19, and there is consequently good immunity among this part of the population.”
Here’s what a Norwegian physician and health official had to say:
“Especially the youngest should consider potential side effects against the benefits of taking this dose.”
—Ingrid Bjerring, Chief Doctor at Lier Municipality
“We did not find sufficient evidence to recommend that this part of the population [younger age bracket] should take a new dose now.… Each vaccine comes with the risk for side effects. Is it then responsible to offer this, when we know that the individual health benefit of a booster likely is low?”
—Are Stuwitz Berg, Department Director at the Norwegian Institute of Public Health
A new Nordic cohort study of 8.9 million participants supports these concerns, finding a nearly nine-fold increase in myocarditis among males aged 12–39 within 28 days of receiving the Moderna COVID-19 booster over those who stopped after two doses.
This mirrors my own findings that myocarditis rates are up 10 times among the vaccinated according to a public healthcare worker survey.
Coauthored by MIT professor and risk management expert Retsef Levi, the Nature article Increased Emergency Cardiovascular Events Among Under-40 Population in Israel During Vaccine Rollout and Third COVID-19 Wave reveals a 25 percent increase in cardiac emergency calls for 16–39-year-olds from January to May 2021 as compared with the previous two years.
The paper cites a study by Israel’s Ministry of Health that “assesses the risk of myocarditis after receiving the 2nd vaccine dose to be between 1 in 3000 to 1 in 6000 in men of age 16–24 and 1 in 120,000 in men under 30.”
A Thai study published in Tropical Medicine and Infectious Disease found cardiovascular manifestations in 29.24 percent of the adolescent cohort—including myopericarditis and tachycardia.
“[W]e need to be upfront that nearly every intervention has some risk, and the coronavirus vaccine is no different. The most significant risk is myocarditis, an inflammation of the heart muscle, which is most common in young men. The CDC cites a rate of 39 myocarditis cases per 1 million second doses given in males 18 to 24. Some studies found a much higher rate; a large Canadian database reported that among men ages 18 to 29 who received the second dose of the Moderna vaccine, the rate of myocarditis was 22 for every 100,000 doses.”
All over the world, prominent physicians, scientists, politicians, and professors are asking pointed questions about illogical mandates; the safety and efficacy of the vaccines; and the dangers posed by the mRNA technology, spike protein, and lipid nanoparticles—including in the UK, Japan, Australia, Europe, and the US.
Formerly pro-vaxx cardiologists such as Dr. Aseem Malhotra, Dr. Dean Patterson, and Dr. Ross Walker are all saying the COVID vaccines should be immediately stopped due to the significant increase in cardiac diseases, adverse events, and excess mortality observed since their rollout, noting that, “until proven otherwise, these vaccines are not safe.”
Dear Prime Minister @RishiSunak,— Dr Aseem Malhotra (@DrAseemMalhotra) December 18, 2022
YOU have the power to stop the ongoing unnecessary harm that is devastating individuals and families. @Keir_Starmer the Labour Party also lost one of its most decorated doctors @KailashChandOBE to this mRNA product. Please stop this roll out NOW https://t.co/SECbfK9joz
BREAKING:— Dr Aseem Malhotra (@DrAseemMalhotra) December 16, 2022
President of the international vascular society raises concerns about covid vaccines in relation to cardiovascular problems.
‘It would be great if someone can show us the light of where to go from here’
We must pause the mRNA jab now to stop more unnecessary harm pic.twitter.com/gIZr19SVl8
And now, perhaps most notably, Dr. John Campbell has performed a 180-degree turn on his previous position and is saying it is time to pause the mass vaccination program “due to the risks associated with the vaccines”:
A Rasmussen poll published on December 7, 2022, found 7 percent of vaccinated respondents have suffered major side effects—a percentage that echoes the 7.7 percent of V-Safe users who sought medical care as well as my own polling data.
Add the 34 percent who reported experiencing minor side effects, and you have nearly 72 million adults who’ve been hit with side effects from the vaccine.
Rasmussen Head Pollster Mark Mitchell explains:
“With 7% having a major side effect, that means over 12 million adults in the US have experienced a self-described major side effect that they attribute to the COVID-19 vaccine. That’s over 11 times the reported COVID death numbers. And also note that anyone who may have died from the vaccine obviously can’t tell us that in the poll.”
“The Pfizer and Moderna trials are both showing a clear signal of increased risk of serious adverse events among the vaccinated.…
“The trial data are indicating that we’re seeing about an elevated risk of these serious adverse events of around 1 in 800 people vaccinated.… That is much, much more common than what you see for other vaccines, where the reported rates are in the range of 1 or 2 per million vaccinees. In these trials, we’re seeing 1 in every 800. And this is a rate that in past years has had vaccines taken off the market.…
“We’re talking about randomized trials … which are widely considered the highest-quality evidence, and we’re talking about the trials that were submitted by Pfizer and Moderna that supported the regulators’ authorization.”
Dr Peter Doshi senior editor of the BMJ wants to know why we haven't already #StoptheShots when 1 in 800 are seriously harmed, yet previous vaccines were suspended for harming 'only' 1 in 100'000.— Porridge2022 (@porridge2022) December 16, 2022
Beats me too! pic.twitter.com/llT4JwL5WQ
And this is the same Pfizer data the FDA tried to keep hidden from the public for 75 years.
Nothing to see here … except 1,223 deaths, 158,000 adverse events, and 1,291 side effects reported in the first 90 days according to the 5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports—and those numbers are likely underreported by a factor of at least 10 (my conservative calculations show an underreporting factor (URF) of 41 for VAERS).
Stanford is asking students to risk a 1 in 800 chance of serious adverse events—meaning the kind of events that can land you in the hospital, disable you, and kill you. And for what?
Anyone who knows how to perform a cost-benefit analysis can see this is all cost and zero benefit.
Stanford’s own Dr. John Ioannidis—professor of medicine, epidemiology & population health, statistics, and biomedical data science—demonstrated that college students are at a near-zero risk of dying from COVID-19 in his “Age-Stratified Infection Fatality Rate of COVID-19 in the Non-Elderly Population.”
One of the six most-cited scientists in the world, Ioannidis found the median IFR was 0.0003 percent for those under 20 and 0.002 percent for twenty-somethings, concluding the fatalities “are lower than pre-pandemic years when only the younger age strata are considered” and that “the IFR in non-elderly individuals was much lower than previously thought.”
And yet Ioannidis’s employer is mandating an experimental product with extensively documented risks of severe harm.
What if a Stanford student dies and the coroner determines it was caused by the vaccine? That happened with George Watts Jr., a 24-year-old college student whose cause of death Chief Deputy Coroner Timothy Cahill Jr. attributed to “COVID-19 vaccine-related myocarditis.” Cahill says, “The vaccine caused the heart to go into failure.”
“We are revoking our vaccination policy and will no longer require students, employees, and visitors to be vaccinated to come to campus.”
The timing is interesting, don’t you think? I’m sure it’s just a coincidence—even though this Clinical Research in Cardiology paper determined vaccine-induced myocardial inflammation was the cause of death in “five persons who have died unexpectedly within seven days following anti-SARS-CoV-2-vaccination.” In that analysis, the authors “establish the histological phenotype of lethal vaccination-associated myocarditis.”
Coincidences notwithstanding, Stanford may want to revoke the mandate before anything like that happens to one of its students … if it hasn’t already.
“Mandating COVID-19 vaccines under an EUA is legally and ethically problematic. The act authorizing the FDA to issue EUAs requires the secretary of the Department of Health and Human Services (HHS) to specify whether individuals may refuse the vaccine and the consequences for refusal. Vaccine mandates are unjustified because an EUA requires less safety and efficacy data than full Biologics License Application (BLA) approval.”
Dr. Naomi Wolf delivered an impassioned speech to her alma mater, Yale, in which she called their booster mandate “a serious crime. It is deeply illegal. Certainly, it violates Title IX.” She explains:
“Title IX commits the university to not discriminate on the basis of sex or gender in getting an equal education.… I oversee a project in which 3,500 experts review the Pfizer documents released under court order by a lawsuit. In that document, there is catastrophic harm to women! And especially to young women! And especially to their reproductive health.… 72% of those with adverse events in the Pfizer documents are women!”
Other universities are currently facing lawsuits for mandating the COVID vaccine in violation of state laws, including one against Ohio University, University of Cincinnati, Bowling Green State University, and Miami University of Ohio.
Abundant evidence proves the vaccines FAIL to:
prevent contraction of COVID
lower hospitalization rates
By the same token, this evidence shows the vaccines are ASSOCIATED with:
heightened transmission levels
greater chances of catching COVID
increased hospitalization rates
higher excess mortality
disproportionate injuries to women
Why is Stanford mandating these unsafe and ineffective products, again?
If logic, peer-reviewed studies, and legal concerns such as the violation of Title IX don’t convince Stanford to rescind the mandate, then what about its stated ethical commitment to upholding its Code of Conduct?
BMJ’s Journal of Medical Ethics recently published COVID-19 Vaccine Boosters for Young Adults: A Risk Benefit Assessment and Ethical Analysis of Mandate Policies at Universities. In this paper, eminent researchers from Harvard, Oxford, Johns Hopkins, and UC San Francisco (among other institutions) present five reasons university mandates are unethical.
They argue that the vaccines:
“(1) are not based on an updated (Omicron era) stratified risk-benefit assessment for this age group; (2) may result in a net harm to healthy young adults; (3) are not proportionate: expected harms are not outweighed by public health benefits given modest and transient effectiveness of vaccines against transmission; (4) violate the reciprocity principle because serious vaccine-related harms are not reliably compensated due to gaps in vaccine injury schemes; and (5) may result in wider social harms.” (emphases mine here and below)
They calculate that:
“To prevent one COVID-19 hospitalisation over a 6-month period, we estimate that 31,207–42,836 young adults aged 18–29 years must receive a third mRNA vaccine.”
The authors conclude that:
“university COVID-19 vaccine mandates are likely to cause net expected harms to young healthy adults—for each hospitalisation averted we estimate approximately 18.5 SAEs and 1,430–4,626 disruptions of daily activities.… these severe infringements of individual liberty and human rights are ethically unjustifiable.”
This builds on a previously published BMJ Global Health article by some of the same authors titled, “The Unintended Consequences of COVID-19 Vaccine Policy: Why Mandates, Passports, and Restrictions May Cause More Harm Than Good.”
In this paper, the authors contend that COVID-19 vaccine mandates “have unintended harmful consequences and may not be ethical, scientifically justified, and effective” and “may prove to be both counterproductive and damaging to public health.”
Over the course of history, countless products once thought to be safe—from DDT to cigarettes to thalidomide for pregnant women to Vioxx—were eventually discovered to be dangerous and even lethal. Responsible governments, agencies, and companies pull those products from the market when the scientific data proves harm—and institutions that care about their community members certainly don’t mandate those products when evidence of risk becomes obvious, as is the case now for the experimental COVID vaccines.
Mahatma Gandhi once stated:
“An error does not become truth by reason of multiplied propagation, nor does truth become error because nobody sees it. Truth stands, even if there be no public support. It is self-sustained.”
The truth is clear to anyone who’s willing to look.
Will it stand up for the lives and health of its students—or will it wait until tragedy strikes another George Watts Jr. or Megha Thakur?
This is a historic opportunity for Stanford to prove its allegiance to people, scientific data, and critical thought over pharmaceutical donors, political pressures, and conformist thinking.
The stakes could not be higher.
* * *
For 16.4 cents/day (annual) or 19.7 cents/day (monthly), you can help Margaret fight tyranny while enjoying access to premium content like Memes by Themes, “rolling” interviews, podcasts, Behind the Scenes, and other bonus content:
Why Is There A COVID Vaccine Mandate For Students?
“Markets Are Tense”: Futures Slide As Central Bank Jitters Rise
EY Eyes Comeback for Biopharma M&A
Five Consumer Staples Stocks to Consider as Recession Shields
IMF projects global growth at 2.9%; Disinflation to bring little comfort
Early diagnosis and monitoring of lupus nephritis – on your smartphone
Genomic methods aid study of Seattle 2017-2022 Shigella outbreak
Hedges: Ukraine, The War That Went Wrong
Is Emerging Markets Debt Well Positioned?
Biden To End COVID-19 Emergency Declarations On May 11, Also Ends Title 42 Policy At Border
International4 hours ago
Why Is There A COVID Vaccine Mandate For Students?
International24 hours ago
Five Consumer Staples Stocks to Consider as Recession Shields
Uncategorized10 hours ago
MAA REPORTS FOURTH QUARTER AND FULL YEAR 2022 RESULTS
Spread & Containment9 hours ago
Early diagnosis and monitoring of lupus nephritis – on your smartphone
Uncategorized12 hours ago
Wonderful companies at wonderful prices?
Uncategorized7 hours ago
Tennessee Population Grows As Residents Leave More Liberal States
Uncategorized17 hours ago
Robotic process automation market 2023-2027: A descriptive analysis of five forces model, market dynamics, and segmentation – Technavio
Uncategorized19 hours ago
Fed Preview: 25bps And Then “The End Is Very Much In Sight”